CompanyNRSN NRSNWNasdaqHerzliya, L3

NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics develops PrimeC, an oral therapy targeting neuroinflammation, oxidative stress, and iron metabolism in amyotrophic lateral sclerosis and Alzheimer's disease.

Stories only

SEC EDGAR ClinicalTrials.gov neurosense-tx.com

6-KSep 25Latest SEC filing

Aug 13Latest story

August 2026

NeuroSense CEO updates shareholders on PARAGON financing, Canada filing, Nasdaq issue

Aug 13PeopleNeuroSense Therapeutics Ltd.

June 2026

NeuroSense says Phase 2b ALS trial hit primary TDP-43 endpoint

Jun 29Clinical readoutNeuroSense Therapeutics Ltd.